CannaPharmaRX Expands Cannabis Exports, Projects $1M+ Q3 Revenue
CannaPharmaRX (OTC PINK:CPMD), a cannabis cultivation and export company, has announced significant expansion in its international operations. The company has completed a 139.6 kg shipment to Germany in July and plans additional shipments totaling 300 kg to Germany and Portugal in August, along with 142 kg to Israel.
To meet growing demand, CannaPharmaRX will open its sixth growing room in September. The company projects Q3 2025 revenues of approximately CAD $1,050,000. Additionally, CannaPharmaRX is working with Fasken Law Firm to address regulatory matters with the BCSC, with a response expected by end of August.
CannaPharmaRX (OTC PINK:CPMD), azienda specializzata nella coltivazione ed esportazione di cannabis, ha annunciato un notevole ampliamento delle operazioni internazionali. A luglio la societ脿 ha completato una spedizione di 139,6 kg in Germania e prevede spedizioni aggiuntive per un totale di 300 kg verso Germania e Portogallo in agosto, oltre a 142 kg verso Israele.
Per soddisfare la domanda crescente, CannaPharmaRX aprir脿 la sua sesta sala di coltivazione a settembre. L'azienda stima ricavi per il terzo trimestre 2025 pari a circa CAD $1.050.000. Inoltre, CannaPharmaRX sta collaborando con lo studio legale Fasken per risolvere questioni regolamentari con la BCSC, con una risposta attesa entro la fine di agosto.
CannaPharmaRX (OTC PINK:CPMD), compa帽铆a dedicada al cultivo y exportaci贸n de cannabis, ha anunciado una importante expansi贸n de sus operaciones internacionales. En julio complet贸 un env铆o de 139,6 kg a Alemania y planea env铆os adicionales por un total de 300 kg a Alemania y Portugal en agosto, adem谩s de 142 kg a Israel.
Para satisfacer la creciente demanda, CannaPharmaRX abrir谩 su sexta sala de cultivo en septiembre. La empresa proyecta ingresos en el tercer trimestre de 2025 de aproximadamente CAD $1.050.000. Adem谩s, CannaPharmaRX trabaja con el bufete Fasken para tratar asuntos regulatorios con la BCSC, esperando una respuesta para finales de agosto.
CannaPharmaRX (OTC PINK:CPMD)電� 雽�毵堨磮 鞛鞍 氚� 靾橃稖 須岇偓搿滌劀 甑牅 靷梾鞚� 韥矊 頇曥灔頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 7鞗旍棎 霃呾澕搿� 139.6kg毳� 氚滌啞頄堨溂氅� 8鞗旍棎電� 霃呾澕 氚� 韽ゴ韴皥搿� 齑� 300kg瓿� 頃粯 鞚挫姢霛检棙搿� 142kg 於旉皜 氚滌啞鞚� 瓿勴殟頃橁碃 鞛堨姷雼堧嫟.
歃濌皜頃橂姅 靾橃殧鞐� 雽�鞚戫晿旮� 鞙勴暣 CannaPharmaRX電� 9鞗旍棎 鞐劘 氩堨Ц 鞛鞍鞁れ潉 臧滌灔頃� 鞓堨爼鞛呺媹雼�. 須岇偓電� 2025雲� 3攵勱赴 毵れ稖鞚� 鞎� CAD $1,050,000搿� 鞓堨儊頃橁碃 鞛堨姷雼堧嫟. 霕愴暅 CannaPharmaRX電� Fasken 氩曤靷靻岇檧 順戨牓頃� BCSC鞕�鞚� 攴滌牅 氍胳牅毳� 觳橂Μ 欷戩澊氅�, 8鞗� 毵愱箤歆� 雼惦硛鞚� 氚涭潉 瓴冹溂搿� 旮半寑頃橁碃 鞛堨姷雼堧嫟.
CannaPharmaRX (OTC PINK:CPMD), soci茅t茅 sp茅cialis茅e dans la culture et l'exportation de cannabis, a annonc茅 une expansion significative de ses op茅rations internationales. En juillet, elle a effectu茅 un envoi de 139,6 kg vers l'Allemagne et pr茅voit d'autres exp茅ditions totalisant 300 kg vers l'Allemagne et le Portugal en ao没t, ainsi que 142 kg vers Isra毛l.
Pour r茅pondre 脿 la demande croissante, CannaPharmaRX ouvrira sa sixi猫me salle de culture en septembre. La soci茅t茅 pr茅voit des revenus pour le T3 2025 d'environ CAD $1 050 000. De plus, CannaPharmaRX collabore avec le cabinet Fasken pour traiter des questions r茅glementaires avec la BCSC, une r茅ponse 茅tant attendue d'ici la fin ao没t.
CannaPharmaRX (OTC PINK:CPMD), ein Unternehmen f眉r Cannabis-Anbau und -Export, hat eine deutliche Ausweitung seiner internationalen Aktivit盲ten angek眉ndigt. Im Juli wurde eine Lieferung von 139,6 kg nach Deutschland abgeschlossen, und f眉r August sind weitere Lieferungen in H枚he von insgesamt 300 kg nach Deutschland und Portugal sowie 142 kg nach Israel geplant.
Um der steigenden Nachfrage gerecht zu werden, wird CannaPharmaRX im September seinen sechsten Anbauraum er枚ffnen. Das Unternehmen rechnet mit Einnahmen f眉r das dritte Quartal 2025 von rund CAD $1.050.000. Zudem arbeitet CannaPharmaRX mit der Kanzlei Fasken zusammen, um regulatorische Angelegenheiten mit der BCSC zu kl盲ren; eine Antwort wird bis Ende August erwartet.
- Completed successful 139.6 kg cannabis shipment to Germany in July
- Planned additional shipments of 300 kg to Germany and Portugal in August
- Expanding market presence with 142 kg shipment to Israel
- Q3 2025 revenue projected at CAD $1,050,000
- Expanding production capacity with sixth growing room opening
- Ongoing regulatory matters with BCSC requiring attention
- Revenue forecast subject to currency exchange rate fluctuations
CREMONA, AB / / August 19, 2025 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an emerging leader in global cannabis cultivation and exports, announces a series of strategic developments. The goal is to strengthen its international footprint and production capacity.
The company continues to make significant steps in its mission to supply premium cannabis products to high-demand international markets, including Germany, Portugal, and Israel. Here's an overview of their recent shipments along with the Q3 revenue estimate.
Major Cannabis Shipments to Europe
Building on its successful export operations, CannaPharmaRX has completed its second shipment to Germany in July by delivering 139.6 kilograms. Demand remains strong in Germany for our product, and we continue to take new orders for our strains.
In August, the company plans to execute two additional shipments to Germany and Portugal totaling 300 kilograms:
鈼� 180.2 kg of high-THC products marking continued interest in our premium products.
鈼� 119.8 kg of low-THC products for the more economical strains that we are producing.
Expanding Presence in Israel
In addition to its European exports, CannaPharmaRX is also preparing a shipment of
approximately 142 kg of medium-quality cannabis buds to Israel. This is another step in the company's strategy to diversify its customer base and strengthen trade relationships in international markets. We are deliberately growing strains that cater to different consumers and different pricing needs so that we are scaling across all sectors.
Scaling Up Production with a New Growing Room
To meet increasing demand, CannaPharmaRX plans to open its sixth growing room in
September, bringing it closer to its total capacity of ten potential grow rooms. The expansion will also allow the company to cultivate new, recently tested cannabis varieties that have delivered promising results during trials.
Strong Q3 Revenue Forecast
The company projects third-quarter revenues of approximately
CTO Update
CannaPharmaRX continues to address regulatory matters in Canada with the BCSC. The company will submit a detailed response to the latest communication received in May by the end of August, with legal guidance from Fasken Law Firm.
Contact:
Company: CannapharmaRx
Name: Constantine Nkafu
Website:
Phone: 403-637-0420
Mail: [email protected]
SOURCE: CannaPharmaRx
View the original on ACCESS Newswire
FAQ
What is CannaPharmaRX's (CPMD) projected revenue for Q3 2025?
How much cannabis is CPMD shipping to European markets in recent deals?
What expansion plans does CannaPharmaRX have for production capacity?
Which international markets is CannaPharmaRX (CPMD) currently serving?
What regulatory challenges is CannaPharmaRX currently facing?
